Tumor burden in patients with early and intermediate-stage hepatocellular carcinoma undergoing liver resection: a retrospective multicenter study on clinical and oncological outcomes

被引:3
|
作者
Martin, David [1 ]
Smet, Heloise [1 ]
Costa, Ana Cristina Da Silva [1 ]
Halkic, Nermin [1 ]
Uldry, Emilie [1 ]
Tabrizian, Parissa [2 ]
Schwartz, Myron [2 ]
Mahamid, Ahmad [2 ]
Goumard, Claire [3 ]
Scatton, Olivier [3 ]
Perinel, Julie [4 ]
Adham, Mustapha [4 ]
Demartines, Nicolas [1 ]
Melloul, Emmanuel [1 ,5 ]
机构
[1] Univ Lausanne UNIL, Univ Hosp CHUV, Dept Visceral Surg, Lausanne, Switzerland
[2] Icahn Sch Med Mt Sinai, Recanati Miller Transplantat Inst, Dept Liver Surg, New York, NY USA
[3] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, Dept Hepatobiliary Surg & Liver Transplantat,CRSA, Paris, France
[4] Hosp Civils Lyon, Edouard Herriot Hosp, Dept Hepatobiliary & Pancreat Surg, Lyon, France
[5] Lausanne Univ Hosp CHUV, Dept Visceral Surg, CH-1011 Lausanne, Switzerland
关键词
TRANSARTERIAL CHEMOEMBOLIZATION; EFFICACY; PROPOSAL; SAFETY; SCORE;
D O I
10.1016/j.hpb.2023.04.001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: According to the Barcelona Clinic Liver Cancer (BCLC) staging system, liver resection (LR) is recommended for early-stage (BCLC-A) hepatocellular carcinoma (HCC) but not for intermediatestage (BCLC-B). This study aimed to assess the outcomes of LR in these patients using a subclassifiMethods: All consecutive patients that underwent LR for BCLC-A and BCLC-B HCC between 01/2010 and 12/2020 in 4 tertiary referral centers were included. Clinical outcomes and overall survival (OS) were assessed in relation to TBS and BCLC stages.Results: Among 612 patients included, 562 were classified as BCLC-A and 50 as BCLC-B. The incidence of overall postoperative complications (56.0 vs 41.5%, p = 0.053) and mortality (0 vs 1.6%, p = 1.000) were similar between BCLC-A and BCLC-B patients. OS was significantly higher for BCLC A/low TBS than BCLC B/low TBS (p = 0.009), while patients with medium and high TBS had similar OS, irrespective of BCLC stage (respectively p = 0.103 and p = 0.343).Conclusions: Patients with medium and high TBS had comparable OS and DFS, irrespective of BCLC A or B stage, and postoperative morbidity was comparable. These results highlight the need for refinement of the BCLC staging system, and LR could be considered for selected intermediate stage (BCLC-B) according to the tumour burden.
引用
收藏
页码:836 / 844
页数:9
相关论文
共 50 条
  • [1] Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan
    Tada, Toshifumi
    Kumada, Takashi
    Toyoda, Hidenori
    Tsuji, Kunihiko
    Hiraoka, Atsushi
    Itobayashi, Ei
    Nouso, Kazuhiro
    Kariyama, Kazuya
    Ishikawa, Toru
    Hirooka, Masashi
    Hiasa, Yoichi
    CANCER SCIENCE, 2017, 108 (07) : 1414 - 1420
  • [2] Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study
    Hu, Zili
    Wang, Xiaohui
    Fu, Yizhen
    Yang, Dinghua
    Zhou, Zhongguo
    Chen, Minshan
    Song, Xin
    Zhang, Yaojun
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (02) : 1019 - 1027
  • [3] A commentary on 'Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study'
    Gao, Fengwei
    Zhao, Xin
    Xie, Qingyun
    Yang, Jiayin
    Wu, Hong
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (04) : 2442 - 2443
  • [4] A commentary on 'Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study'
    Rui, Chunhua
    Piao, Longhuan
    Wang, Peng
    INTERNATIONAL JOURNAL OF SURGERY, 2025, 111 (01) : 1648 - 1649
  • [5] Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria
    Hung, Ya-Wen
    Lee, I-Cheng
    Chi, Chen-Ta
    Lee, Rheun-Chuan
    Liu, Chien-An
    Chiu, Nai-Chi
    Hwang, Hsuen-En
    Chao, Yee
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    LIVER CANCER, 2021, 10 (06) : 629 - 640
  • [6] Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma
    Chen, Shuling
    Jin, Huilin
    Dai, Zihao
    Wei, Mengchao
    Xiao, Han
    Su, Tianhong
    Li, Bin
    Liu, Xin
    Wang, Yu
    Li, Jiaping
    Shen, Shunli
    Zhou, Qi
    Peng, Baogang
    Peng, Zhenwei
    Peng, Sui
    CANCER MEDICINE, 2019, 8 (04): : 1530 - 1539
  • [7] LIVER RESECTION VERSUS TRANSARTERIAL CHEMOEMBOLIZATION FOR THE TREATMENT OF INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA
    Zhu, Wanjie
    Chen, Shuling
    Jin, Huilin
    GUT, 2019, 68 : A128 - A128
  • [8] Letter to the editor: Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study
    Zhao, Jianping
    Wang, Jingjing
    Zhang, Wanguang
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (07) : 4409 - 4410
  • [9] Tumor burden score as a prognostic factor in patients with intermediate and locally advanced hepatocellular carcinoma undergoing liver resection
    Wei, You-Fei
    Xu, Yin-Feng
    HPB, 2024, 27 (03) : 422 - 423
  • [10] The efficacy and safety of lenvatinib in patients with intermediate-stage hepatocellular carcinoma: A nationwide multicenter study in Japan
    Tsuchiya, Kaoru
    Kurosaki, Masayuki
    Sakamoto, Azusa
    Marusawa, Hiroyuki
    Ogawa, Chikara
    Kondo, Masahiko
    Joko, Kouji
    Tsuji, Keiji
    Kimura, Hiroyuki
    Wada, Shuichi
    Kobashi, Haruhiko
    Uchida, Yasushi
    Furuta, Koichiro
    Akahane, Takehiro
    Kusakabe, Atsunori
    Yoshida, Hideo
    Matsushita, Tomomichi
    Abe, Takehiko
    Sohda, Tetsuro
    Izumi, Namiki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)